Background:  TPA converts the abundant, but inactive, zymogen plasminogen to plasmin by hydrolyzing a single Arg-Val bond. By controlling plasmin-mediated proteolysis, it plays an important role in tissue remodeling and degradation, cell migration and many other physiopathological events. TPA binds to fibrin with high affinity; this leads to an increase in the catalytic efficiency of the enzyme of 100- to 1000-fold, due to an increase in affinity for plasminogen. Similarly, binding to heparin increases the activation of plasminogen. Binding to laminin and fibronectin has also been demonstrated. TPA also binds to mannose receptor and the low density lipoprotein receptor related protein (LRP1). These proteins are involved in TPA clearance. TPA binds to annexin II and to cytokeratin 8. As yet unidentified interactions on endothelial cells and vascular smooth muscle cells (VSMC) lead to a 100-fold stimulation of plasminogen activation. Binding to VSMC reduces TPA inhibition by PAI-1 by 30-fold.

Description: Rabbit polyclonal to TPA

Immunogen: KLH conjugated synthetic peptide derived from TPA

Specificity:  ·Reacts with Human, Mouse, Pig and Rat.

·Isotype: IgG

Application:  ·Western blotting: 1/100-500. Predicted Mol wt: 62 kDa;

·Immunohistochemistry (Paraffin/frozen tissue section): 1/100-200;

·Immunocytochemistry: 1/100;

·Immunoprecipitation: 1/50;

·ELISA: 1/500;

·Optimal working dilutions must be determined by the end user.